治疗后淋巴细胞减少与中性粒细胞与淋巴细胞比值升高与人乳头瘤病毒阴性口咽癌不良临床结局的相关性
这项单机构回顾性分析纳入1997年1月1日至2017年1月4日治疗的108例HPV阴性口咽癌患者,中位随访37个月。放疗开始后3个月时3-4级淋巴细胞减少与更差的无复发生存和总生存相关,多变量分析中根治性放疗和3-4级淋巴细胞减少与更差总生存相关。作者认为淋巴细胞减少和NLR可能作为临床结局的生物标志物。
要点
- 放疗开始后3个月时3-4级淋巴细胞减少患者3年无复发生存36% vs 63%(HR 0.45)。
- 放疗开始后3个月时3-4级淋巴细胞减少患者3年总生存34% vs 64%(HR 0.45)。
- 多变量分析中根治性放疗(HR 3.3)和3-4级淋巴细胞减少(HR 2.6)与更差总生存相关。
核心结论
- 治疗开始后最早3个月的淋巴细胞减少和NLR可能作为HPV阴性口咽癌患者临床结局的生物标志物。
- 作者认为这些患者可能从辅助治疗强化或更密切监测中获益。
研究设计与样本
- 单机构回顾性分析,纳入1997年1月1日至2017年1月4日治疗的HPV阴性口咽癌患者。
- 共纳入108例HPV阴性口咽癌患者,均有至少1次放疗开始后2至12个月的全血细胞计数;中位随访37个月(范围2-197个月)。
- 干预为手术后继以放疗 vs 根治性放疗,伴或不伴化疗。
- 数据从2017年8月26日至9月7日分析。
主要发现
- 108例患者中87.0%为男性,平均年龄56岁(范围35-84岁);57例接受手术后继以术后放疗,51例接受根治性放疗。
- 治疗期间79例患者中67例(84.8%)发生3-4级淋巴细胞减少,79例中17例(21.5%)发生4级淋巴细胞减少。
- 中性粒细胞绝对计数在放疗后6个月恢复,但淋巴细胞绝对计数在放疗后1年仍处于低水平。
- 放疗开始后3个月时有无3-4级淋巴细胞减少患者的估计3年局部区域控制率为73% vs 82%(HR 0.58,95%CI 0.19-1.8);估计3年无复发生存率为36% vs 63%(HR 0.45,95%CI 0.23-0.87);估计3年总生存率为34% vs 64%(HR 0.45,95%CI 0.23-0.88)。
- 多变量分析中,放疗后3个月时根治性放疗(HR 3.3,95%CI 1.6-7.1)和3-4级淋巴细胞减少(HR 2.6,95%CI 1.3-5.5)与更差总生存相关。
临床怎么用
- 作者认为治疗开始后最早3个月的淋巴细胞减少和NLR可能作为HPV阴性口咽癌患者临床结局的生物标志物。
- 作者认为这些患者可能从辅助治疗强化或更密切监测中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Better biomarkers are needed for human papillomavirus (HPV)-negative oropharyngeal cancer (OPC) to identify patients at risk of recurrence. Lymphopenia and an elevated ratio of neutrophils to lymphocytes (NLR) have been associated with poor disease outcomes in a number of solid tumors. OBJECTIVE: To test the hypothesis that postradiotherapy lymphopenia and elevated NLR are associated with poor clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: This single-institution retrospective analysis included patients with HPV-negative OPC treated from January 1, 1997, through January 4, 2017. Median follow-up was 37 months (range, 2-197 months). A total of 108 patients with HPV-negative OPC and at least 1 complete blood cell count 2 to 12 months after the start of radiotherapy were included. Data were analyzed from August 26 to September 7, 2017. INTERVENTIONS: Surgery followed by radiotherapy vs definitive radiotherapy, with or without chemotherapy. MAIN OUTCOMES AND MEASURES: Absolute lymphocyte (ALC) and absolute neutrophil (ANC) counts were tested as variables affecting locoregional control, recurrence-free survival, and overall survival. RESULTS: Of a total of 108 patients included in the analysis (87.0% male; mean age, 56 years [range, 35-84 years]), 57 received surgery followed by postoperative radiotherapy and 51 received definitive radiotherapy. During treatment, 67 of 79 patients (84.8%) had grades 3 to 4 lymphopenia and 17 of 79 (21.5%) had grade 4 lymphopenia. The ANC recovered by 6 months after radiotherapy, but ALC remained depressed to 1 year after radiotherapy. Posttreatment lymphopenia and elevated NLR were associated with worse recurrence-free and overall survival. The estimated 3-year LRC in patients with and without grades 3 to 4 lymphopenia at 3 months after radiotherapy start was 73% vs 82% (hazard ratio [HR], 0.58; 95% CI, 0.19-1.8); estimated 3-year recurrence-free survival, 36% vs 63% (HR, 0.45; 95% CI, 0.23-0.87); and estimated 3-year overall survival, 34% vs 64% (HR, 0.45; 95% CI, 0.23-0.88). In multivariable analysis, an association with worse overall survival was found for definitive radiotherapy (HR, 3.3; 95% CI, 1.6-7.1) and grades 3 to 4 lymphopenia (HR, 2.6; 95% CI, 1.3-5.5) at 3 months after radiotherapy. CONCLUSIONS AND RELEVANCE: Lymphopenia and NLR as early as 3 months after treatment start may serve as biomarkers of clinical outcomes in patients with HPV-negative OPC. These patients may benefit from adjuvant treatment intensification or closer surveillance.
引用
- Lin AJ, Gang M, Rao YJ, et al. Association of Posttreatment Lymphopenia and Elevated Neutrophil-to-Lymphocyte Ratio With Poor Clinical Outcomes in Patients With Human Papillomavirus-Negative Oropharyngeal Cancers. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 30920592. doi:10.1001/jamaoto.2019.0034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。